Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Oxymatrine prevents hypoxia- and monocrotaline-induced pulmonary hypertension in rats.

Zhang B, Niu W, Xu D, Li Y, Liu M, Wang Y, Luo Y, Zhao P, Liu Y, Dong M, Sun R, Dong H, Li Z.

Free Radic Biol Med. 2014 Apr;69:198-207. doi: 10.1016/j.freeradbiomed.2014.01.013. Epub 2014 Jan 15.

PMID:
24440469
2.

Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension.

Preston IR, Sagliani KD, Warburton RR, Hill NS, Fanburg BL, Jaffe IZ.

Am J Physiol Lung Cell Mol Physiol. 2013 May 15;304(10):L678-88. doi: 10.1152/ajplung.00300.2012. Epub 2013 Mar 1.

3.

Resveratrol alleviate hypoxic pulmonary hypertension via anti-inflammation and anti-oxidant pathways in rats.

Xu D, Li Y, Zhang B, Wang Y, Liu Y, Luo Y, Niu W, Dong M, Liu M, Dong H, Zhao P, Li Z.

Int J Med Sci. 2016 Nov 23;13(12):942-954. eCollection 2016 Nov 23.

4.

Sodium tanshinone IIA sulfonate inhibits canonical transient receptor potential expression in pulmonary arterial smooth muscle from pulmonary hypertensive rats.

Wang J, Jiang Q, Wan L, Yang K, Zhang Y, Chen Y, Wang E, Lai N, Zhao L, Jiang H, Sun Y, Zhong N, Ran P, Lu W.

Am J Respir Cell Mol Biol. 2013 Jan;48(1):125-34. doi: 10.1165/rcmb.2012-0071OC. Epub 2012 Oct 11.

5.

Nitrite potently inhibits hypoxic and inflammatory pulmonary arterial hypertension and smooth muscle proliferation via xanthine oxidoreductase-dependent nitric oxide generation.

Zuckerbraun BS, Shiva S, Ifedigbo E, Mathier MA, Mollen KP, Rao J, Bauer PM, Choi JJ, Curtis E, Choi AM, Gladwin MT.

Circulation. 2010 Jan 5;121(1):98-109. doi: 10.1161/CIRCULATIONAHA.109.891077. Epub 2009 Dec 21.

6.

Critical role for the advanced glycation end-products receptor in pulmonary arterial hypertension etiology.

Meloche J, Courchesne A, Barrier M, Carter S, Bisserier M, Paulin R, Lauzon-Joset JF, Breuils-Bonnet S, Tremblay É, Biardel S, Racine C, Courture C, Bonnet P, Majka SM, Deshaies Y, Picard F, Provencher S, Bonnet S.

J Am Heart Assoc. 2013 Jan 16;2(1):e005157. doi: 10.1161/JAHA.112.005157.

7.

Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats.

Csiszar A, Labinskyy N, Olson S, Pinto JT, Gupte S, Wu JM, Hu F, Ballabh P, Podlutsky A, Losonczy G, de Cabo R, Mathew R, Wolin MS, Ungvari Z.

Hypertension. 2009 Sep;54(3):668-75. doi: 10.1161/HYPERTENSIONAHA.109.133397. Epub 2009 Jul 13.

8.

Involvement of asymmetric dimethylarginine and Rho kinase in the vascular remodeling in monocrotaline-induced pulmonary hypertension.

Li XH, Peng J, Tan N, Wu WH, Li TT, Shi RZ, Li YJ.

Vascul Pharmacol. 2010 Nov-Dec;53(5-6):223-9. doi: 10.1016/j.vph.2010.09.002. Epub 2010 Sep 16.

PMID:
20840872
9.

Hydrogen ameliorates pulmonary hypertension in rats by anti-inflammatory and antioxidant effects.

Kishimoto Y, Kato T, Ito M, Azuma Y, Fukasawa Y, Ohno K, Kojima S.

J Thorac Cardiovasc Surg. 2015 Sep;150(3):645-54.e3. doi: 10.1016/j.jtcvs.2015.05.052. Epub 2015 May 22.

PMID:
26095621
10.

Resveratrol reverses monocrotaline-induced pulmonary vascular and cardiac dysfunction: a potential role for atrogin-1 in smooth muscle.

Paffett ML, Lucas SN, Campen MJ.

Vascul Pharmacol. 2012 Jan-Feb;56(1-2):64-73. doi: 10.1016/j.vph.2011.11.002. Epub 2011 Nov 25.

11.

Pathophysiological roles of nuclear factor kappaB (NF-kB) in pulmonary arterial hypertension: effects of synthetic selective NF-kB inhibitor IMD-0354.

Hosokawa S, Haraguchi G, Sasaki A, Arai H, Muto S, Itai A, Doi S, Mizutani S, Isobe M.

Cardiovasc Res. 2013 Jul 1;99(1):35-43. doi: 10.1093/cvr/cvt105. Epub 2013 Apr 30.

PMID:
23631839
12.

Mitochondrial hyperpolarization in pulmonary vascular remodeling. Mitochondrial uncoupling protein deficiency as disease model.

Pak O, Sommer N, Hoeres T, Bakr A, Waisbrod S, Sydykov A, Haag D, Esfandiary A, Kojonazarov B, Veit F, Fuchs B, Weisel FC, Hecker M, Schermuly RT, Grimminger F, Ghofrani HA, Seeger W, Weissmann N.

Am J Respir Cell Mol Biol. 2013 Sep;49(3):358-67. doi: 10.1165/rcmb.2012-0361OC.

PMID:
23590303
13.

Lysyl oxidases play a causal role in vascular remodeling in clinical and experimental pulmonary arterial hypertension.

Nave AH, Mižíková I, Niess G, Steenbock H, Reichenberger F, Talavera ML, Veit F, Herold S, Mayer K, Vadász I, Weissmann N, Seeger W, Brinckmann J, Morty RE.

Arterioscler Thromb Vasc Biol. 2014 Jul;34(7):1446-58. doi: 10.1161/ATVBAHA.114.303534. Epub 2014 May 15.

14.

Role of Src tyrosine kinases in experimental pulmonary hypertension.

Pullamsetti SS, Berghausen EM, Dabral S, Tretyn A, Butrous E, Savai R, Butrous G, Dahal BK, Brandes RP, Ghofrani HA, Weissmann N, Grimminger F, Seeger W, Rosenkranz S, Schermuly RT.

Arterioscler Thromb Vasc Biol. 2012 Jun;32(6):1354-65. doi: 10.1161/ATVBAHA.112.248500. Epub 2012 Apr 19.

15.
16.

Upregulation of profilin, cofilin-2 and LIMK2 in cultured pulmonary artery smooth muscle cells and in pulmonary arteries of monocrotaline-treated rats.

Dai YP, Bongalon S, Tian H, Parks SD, Mutafova-Yambolieva VN, Yamboliev IA.

Vascul Pharmacol. 2006 May;44(5):275-82. Epub 2006 Mar 9.

PMID:
16524786
17.

Intratracheal Administration of Prostacyclin Analogue-incorporated Nanoparticles Ameliorates the Development of Monocrotaline and Sugen-Hypoxia-induced Pulmonary Arterial Hypertension.

Akagi S, Nakamura K, Matsubara H, Kondo M, Miura D, Matoba T, Egashira K, Ito H.

J Cardiovasc Pharmacol. 2016 Apr;67(4):290-8. doi: 10.1097/FJC.0000000000000352.

18.

Positive feedback-loop of telomerase reverse transcriptase and 15-lipoxygenase-2 promotes pulmonary hypertension.

Shen T, Ma J, Zhang L, Yu X, Liu M, Hou Y, Wang Y, Ma C, Li S, Zhu D.

PLoS One. 2013 Dec 23;8(12):e83132. doi: 10.1371/journal.pone.0083132. eCollection 2013 Dec 23.

20.

PAR-2 inhibition reverses experimental pulmonary hypertension.

Kwapiszewska G, Markart P, Dahal BK, Kojonazarov B, Marsh LM, Schermuly RT, Taube C, Meinhardt A, Ghofrani HA, Steinhoff M, Seeger W, Preissner KT, Olschewski A, Weissmann N, Wygrecka M.

Circ Res. 2012 Apr 27;110(9):1179-91. doi: 10.1161/CIRCRESAHA.111.257568. Epub 2012 Mar 29.

Supplemental Content

Support Center